Sarepta has refused to suspend all dosing of its gene therapy for Duchenne muscular dystrophy, Elevidys, defying a clinical hold request from the FDA. The FDA said it had met with Sarepta to ask that ...
Subscribe Login Register Log out My Profile Subscriber Services Search PGe NEWSLETTERS PG STORE ARCHIVES OBITUARIES JOBS PUBLIC NOTICES CLASSIFIEDS EVENTS PETS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback